Clover Health Q2 revenue rises 56%, beating estimates on membership growth
CLOV•Key financial details and analyst coverage
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $743 million | $728.27 million (3 analysts) |
| Q2 Net Income | $28 million | ||
| Q2 Adjusted EBITDA | Beat | $41 million | $30.72 million (3 analysts) |
The current average analyst rating on the shares is hold, with 1 strong buy or buy, 3 hold, and no sell or strong sell ratings.
The average consensus recommendation for the managed healthcare peer group is buy.
Wall Street's median 12-month price target for Clover Health Investments, Corp. is $4.13, about 3.4% below its August 4 closing price of $4.27.
The stock recently traded at 152 times the next 12-month earnings versus a P/E of 2,613 three months ago.
Full-year guidance raised across all metrics
Clover Health raised its 2026 revenue guidance to $2.92 billion-$3.00 billion.
